Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15801034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Juvenile
- Immunoglobulin G
- Lupus Nephritis
- Recombinant Fusion Proteins
- Vasculitis, Leukocytoclastic, Cutaneous